OBJECTIVES To develop and validate a predischarge risk stratification model by using transcutaneous bilirubin (TcB) values and clinical factors to predict significant postdischarge hyperbilirubinemia in healthy term and late preterm Chinese neonates. METHODS In a prospective cohort study, 8215 healthy term and late preterm neonates in 8 hospitals in China underwent TcB measurement at <168 hou...

PURPOSE We evaluated and compared the oxidant and antioxidant status of hyperbilirubinemic infants before and after the two forms of phototherapy: conventional and LED phototherapy, in order to identify the optimal treatment method. METHOD Thirty newborns exposed to conventional (Group I) phototherapy and 30 infants exposed to LED phototherapy (Group II) were studied. The serum total antioxid...

Introduction:The aim of this study is to compare significant post-phototherapy bilirubin rebound in two groups of neonates, with two levels of bilirubin, at discontinuation of phototherapy. Materials and Methods:One hundred and fifteen neonates ≥35 weeks of gestationl age (GA), admitted due to hyperbilirubinemia in the Neonatal Ward of Valiasr Hospital, were randomly divided into two groups: gr...

Therapies to prevent severe neonatal unconjugated hyperbilirubinemia and kernicterus are phototherapy and, in unresponsive cases, exchange transfusion, which has significant morbidity and mortality risks. Neurotoxicity is caused by the fraction of unconjugated bilirubin not bound to albumin (free bilirubin, Bf). Human serum albumin (HSA) administration was suggested to increase plasma bilirubin...

Bakground: Phototherapy plays a significant role in the treatment and prevention of hyperbilirubinemia as well as the management of subsequent complications in the newborn. However, this treatment modality may itself result in the development of hypocalcaemia and create serious complications including convulsion and related condi-

OBJECTIVES Our goal was to assess the impact of programmatic and coordinated use of transcutaneous bilirubinometry (TcB) on the incidence of severe neonatal hyperbilirubinemia and measures of laboratory, hospital, and nursing resource utilization. METHODS We compared the neonatal hyperbilirubinemia-related outcomes of 14 796 prospectively enrolled healthy infants ≥35 weeks gestation offered r...

Bakground: Phototherapy plays a significant role in the treatment and prevention of hyperbilirubinemia as well as the management of subsequent complications in the newborn.  However, this treatment modality may itself result in the development of hypocalcaemia and create serious complications including convulsion and related conditions. Objective: This study was under-taken to investigate photo...

A pigment different from (Z,Z)bilirubin-IX alpha was detected by fluorometric methods in blood specimens from newborn infants undergoing blue-light therapy for unconjugated hyperbilirubinemia; it was not detected in specimens from infants not under therapy. The phototherapy-associated pigment has fluorescence, solubility, and photochemical properties that are identical to those exhibited by wha...

Background: Prolonged hyperbilirubinemia is defined as jaundice persisting more than two and three weeks of life in term and preterm neonates, respectively. In total, 15-40% of jaundiced neonates became prolonged. The most common causes of prolonged hyperbilirubinemia are breastfeeding, infection, hypothyroidism, and continued hemolysis. Given the fact that no study was conducted on the associa...

Background: Fenofibrate is used as an adjunct therapy to reduce bilirubin level and duration of phototherapy. This study was done determine the efficacy fenofibrate in treatment unconjugated neonatal hyperbilirubinemia.&#x0D; Materials &amp; Method: Total 60 neonates were enrolled devided into two groups. In group A, a single dose oral (10mg/kg) given along with phototherapy, Group B only Blood...